Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
193 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Macular Edema - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape. Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 18, 6, 1, 21 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diabetic Macular Edema - Overview 8 Diabetic Macular Edema - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Diabetic Macular Edema - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 22 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Diabetic Macular Edema - Companies Involved in Therapeutics Development 29 Aciont Inc 29 ActiveSite Pharmaceuticals Inc 29 Acucela Inc 30 Aerie Pharmaceuticals Inc 30 Aerpio Therapeutics Inc 31 Alcon Laboratories Inc 31 Allergan Plc 32 Ampio Pharmaceuticals Inc 32 Araim Pharmaceuticals Inc 33 Boehringer Ingelheim GmbH 33 Cell Medica Ltd 34 Chengdu Kanghong Pharmaceuticals Group Co Ltd 34 Clearside BioMedical Inc 35 Coherus BioSciences Inc 35 EyeGate Pharmaceuticals Inc 36 F. Hoffmann-La Roche Ltd 36 Formycon AG 37 Genmab A/S 37 GlaxoSmithKline Plc 38 Icon Bioscience Inc 38 Kala Pharmaceuticals Inc 39 Kalvista Pharmaceuticals Inc 39 Kowa Company Ltd 40 Lupin Ltd 40 Mabion SA 41 Ocular Therapeutix Inc 41 Oculis ehf 42 Ohr Pharmaceutical Inc 42 Pfizer Inc 43 pSivida Corp 43 Regeneron Pharmaceuticals Inc 44 SciFluor Life Sciences LLC 44 Senju Pharmaceutical Co Ltd 45 Stealth BioTherapeutics Inc 45 ThromboGenics NV 46 Verseon Corp 46 Xbrane Biopharma AB 47 Diabetic Macular Edema - Drug Profiles 48 (aflibercept + nesvacumab) - Drug Profile 48 abicipar pegol - Drug Profile 50 ACU-6151 - Drug Profile 53 ACX-107 - Drug Profile 54 aflibercept biosimilar - Drug Profile 55 aflibercept biosimilar - Drug Profile 56 AKB-9778 - Drug Profile 57 ALG-1001 - Drug Profile 62 Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 66 AR-13154 - Drug Profile 67 ARP-1536 - Drug Profile 68 ASPPDC-010 - Drug Profile 69 BI-1026706 - Drug Profile 70 Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 72 brolucizumab - Drug Profile 73 bromfenac sodium - Drug Profile 76 cibinetide - Drug Profile 78 conbercept - Drug Profile 81 danazol - Drug Profile 83 darapladib - Drug Profile 87 dexamethasone acetate - Drug Profile 90 dexamethasone acetate - Drug Profile 96 dexamethasone dipropionate XR - Drug Profile 98 difluprednate - Drug Profile 99 Drug for Diabetic Macular Edema - Drug Profile 100 EBI-031 - Drug Profile 101 elamipretide - Drug Profile 102 fluocinolone acetonide SR - Drug Profile 110 HO-10 - Drug Profile 119 HPV-19 - Drug Profile 120 JDE-006 - Drug Profile 121 KPI-285 - Drug Profile 122 KVD-001 - Drug Profile 123 LKA-651 - Drug Profile 125 NM-108 - Drug Profile 126 OCX-063 - Drug Profile 127 OTX-TKI - Drug Profile 128 PF-655 - Drug Profile 130 Protein to Inhibit VEGF for Ophthalmology - Drug Profile 133 ranibizumab biosimilar - Drug Profile 134 ranibizumab biosimilar - Drug Profile 135 ranibizumab biosimilar - Drug Profile 136 ranibizumab biosimilar - Drug Profile 138 ranibizumab biosimilar - Drug Profile 139 RG-7716 - Drug Profile 140 ripasudil - Drug Profile 142 SF-0166 - Drug Profile 144 Small Molecule for Diabetic Macular Edema - Drug Profile 146 Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 147 Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile 148 squalamine lactate - Drug Profile 149 teprotumumab - Drug Profile 157 THR-149 - Drug Profile 160 THR-317 - Drug Profile 161 triamcinolone acetonide - Drug Profile 164 triamcinolone acetonide - Drug Profile 165 VA-999272 - Drug Profile 172 Diabetic Macular Edema - Dormant Projects 173 Diabetic Macular Edema - Discontinued Products 175 Diabetic Macular Edema - Product Development Milestones 176 Featured News & Press Releases 176 Appendix 188 Methodology 188 Coverage 188 Secondary Research 188 Primary Research 188 Expert Panel Validation 188 Contact Us 188 Disclaimer 189
List of Tables
Number of Products under Development for Diabetic Macular Edema, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2017 Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by Acucela Inc, H2 2017 Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H2 2017 Diabetic Macular Edema - Pipeline by Alcon Laboratories Inc, H2 2017 Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2017 Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H2 2017 Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2017 Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2017 Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Diabetic Macular Edema - Pipeline by Formycon AG, H2 2017 Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2017 Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H2 2017 Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H2 2017 Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H2 2017 Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2017 Diabetic Macular Edema - Pipeline by Mabion SA, H2 2017 Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2017 Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2017 Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H2 2017 Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2017 Diabetic Macular Edema - Pipeline by pSivida Corp, H2 2017 Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2017 Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2017 Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H2 2017 Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2017 Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2017 Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2017 Diabetic Macular Edema - Dormant Projects, H2 2017 Diabetic Macular Edema - Dormant Projects, H2 2017 (Contd..1), H2 2017 Diabetic Macular Edema - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
